Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.67 |
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | HTR1A | P08908 | 7/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1870135 | 1.00 | HSD11B1 (1.00) | HSD11B1ADRA1ADRD2HTR1A | |
| SCHEMBL1871835 | 1.00 | HSD11B1 (1.00) | HSD11B1ADRA1ADRD2HTR1A | |
| SCHEMBL15139395 | 1.00 | HSD11B1 (1.00) | HSD11B1ADRA1ADRD2HTR1A | |
| SCHEMBL1868061 | 1.00 | HSD11B1 (1.00) | HSD11B1ADRA1ADRD2HTR1A | |
| SCHEMBL9964002 | 1.00 | HSD11B1 (1.00) | HSD11B1ADRA1ADRD2HTR1A | |
| SCHEMBL1870138 | 1.00 | HSD11B1 (1.00) | HSD11B1ADRA1ADRD2HTR1A | |
| Hydrochloric Acid SCHEMBL10504772 | 0.99 | HSD11B1 (0.97) | HSD11B1ADRA1ADRD2HTR1A | |
| Hydrochloric Acid SCHEMBL10504838 | 0.99 | HSD11B1 (0.97) | HSD11B1ADRA1ADRD2HTR1A | |
| SCHEMBL8175020 | 0.92 | HSD11B1 (0.84) | HSD11B1ADRA1ADRD2HTR1A | |
| SCHEMBL9119375 | 0.92 | HSD11B1 (0.84) | HSD11B1ADRA1ADRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2496559-B1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE AND THEIR USE AS HSD 1 INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9663470-B2 | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | VITAE PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160272590-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-09-22 | — | — | US | disclosed |
| US-9328072-B2 | Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | VITAE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9120769-B2 | Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | BOEHRINGER-INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-01 | — | — | US | disclosed |
| US-20140249174-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | BOEHRINGER-INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-04 | — | — | US | disclosed |
| US-20140031544-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| EP-2635563-A1 | CRYSTALLINE FORMS OF HYDROCHLORIDE SALT OF (4A-R,9A-S) -1- (1H - BENZOIMIDAZOLE- 5 -CARBONYL) -2, 3, 4, 4A, 9, 9A - HEXAHYDRO -1H- INDENO [2, 1 -B]PYRIDINE- 6 -CARBONITRILE AND THEIR USE AS HSD 1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-09-11 | — | — | EP | disclosed |
| US-8497281-B2 | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| EP-2496559-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | Vitae Pharmaceuticals, Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2012061708-A1 | CRYSTALLINE FORMS OF HYDROCHLORIDE SALT OF (4A-R,9A-S) -1- (1H - BENZOIMIDAZOLE- 5 -CARBONYL) -2, 3, 4, 4A, 9, 9A - HEXAHYDRO -1H- INDENO [2, 1 -B] PYRIDINE- 6 -CARBONITRILE AND THEIR USE AS HSD 1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061708-A1 | CRYSTALLINE FORMS OF HYDROCHLORIDE SALT OF (4A-R,9A-S) -1- (1H - BENZOIMIDAZOLE- 5 -CARBONYL) -2, 3, 4, 4A, 9, 9A - HEXAHYDRO -1H- INDENO [2, 1 -B] PYRIDINE- 6 -CARBONITRILE AND THEIR USE AS HSD 1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | WO | disclosed |
| US-20110136800-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | Boehringer Ingelheim International GmbH Vitae Pharmaceuticals | 2011-06-09 | — | — | US | disclosed |
| US-20110136800-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | Boehringer Ingelheim International GmbH Vitae Pharmaceuticals | 2011-06-09 | — | — | US | disclosed |
| WO-2011057054-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | VITAE PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057054-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | VITAE PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-6262064-B1 | AN ACTAHYDROBENZO(F)QUINOLINE-BASED COMPOUND | THE BOARD OF GOVERNORS FOR HIGHER EDUCATION | 2001-07-17 | — | — | US | disclosed |
| US-6080752-A | FOR TREATING CONDITION WHICH REQUIRES ANTAGONISM OF A DOPAMINE RECEPTOR SUCH AS PSYCHTIC CONDITION | SMITHKLINE BEECHAM PLC (GB) | 2000-06-27 | — | — | US | disclosed |
| EP-0906284-A1 | TRICYCLIC AMINE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997047602-A1 | TRICYCLIC AMINE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1997-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031544-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | HSD17B1, HSD3B1, HSD11B1 | HSD11B1 3/4885ADRA1A 376/4885DRD2 322/4885 |
| US-20140249174-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | HSD17B1, HSD3B1, HSD11B1 | HSD11B1 3/4885ADRA1A 376/4885DRD2 322/4885 |
| US-20110136800-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | HSD17B1, HSD3B1, HSD11B1 | HSD11B1 3/4885ADRA1A 376/4885DRD2 322/4885 |
| US-20160272590-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | HSD17B1, HSD3B1, HSD11B1 | HSD11B1 3/4885ADRA1A 376/4885DRD2 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.